secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0001174947-22-001093
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED Q3 sales $275.1M (+10.6% YoY); adjusted EPS $0.77 misses prior year; narrows 2022 guidance
--------------------------------------------------------------------------------

- Sales $275.1M +10.6% as reported, +12.1% constant currency; domestic +14.2%, international +6.2% as reported.
- GAAP diluted EPS $1.48 (vs $0.47 Q3 2021); adjusted diluted EPS $0.77 (vs $0.80) down 3.8%.
- Full-year 2022 revenue guidance narrowed to $1.1B-$1.115B; adjusted EPS guidance lowered to $3.21-$3.28 from $3.25-$3.45.
- Closed Biorez acquisition on Aug 9, 2022; integrates with recent In2Bones acquisition.
- Orthopedic Surgery sales $118.6M +12.2% as reported; General Surgery $156.5M +9.4%. Single-use +15.1%, capital -8.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000117494722001093/0001174947-22-001093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000117494722001093/form8k-28878_cnmd.htm
  HTML page:      https://secwatch.observer/filing/0001174947-22-001093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer